A gold storm is coming…
“We are in the early stages of a mania – the calm before the storm.”...
[Full Story]
Richard A. Miller  net worth and biography

Richard Miller Biography and Net Worth

Dr. Miller was co-founder and CEO of Pharmacyclics, where he led the initial discovery and development efforts for ibrutinib. Prior to that, he was a co-founder, Vice President and Director of IDEC (which merged to form Biogen IDEC, now Biogen), where he led research efforts on lymphoma culminating in the development of rituximab. He has also founded other private and public biotech companies. Dr. Miller received an M.D. from the State University of New York Medical School. He is a board-certified oncologist and is currently Adjunct Clinical Professor of Medicine (oncology) at Stanford University Medical Center.

What is Richard A. Miller 's net worth?

The estimated net worth of Richard A. Miller is at least $1.20 million as of December 13th, 2022. Dr. Miller owns 1,480,119 shares of Corvus Pharmaceuticals stock worth more than $1,202,745 as of February 7th. This net worth estimate does not reflect any other investments that Dr. Miller may own. Learn More about Richard A. Miller 's net worth.

How do I contact Richard A. Miller ?

The corporate mailing address for Dr. Miller and other Corvus Pharmaceuticals executives is 863 Mitten Road Suite102, BURLINGAME CA, 94010. Corvus Pharmaceuticals can also be reached via phone at (650) 900-4520 and via email at [email protected] Learn More on Richard A. Miller 's contact information.

Has Richard A. Miller been buying or selling shares of Corvus Pharmaceuticals?

Richard A. Miller has not been actively trading shares of Corvus Pharmaceuticals over the course of the past ninety days. Most recently, on Tuesday, December 13th, Richard A. Md Miller bought 50,000 shares of Corvus Pharmaceuticals stock. The stock was acquired at an average cost of $0.74 per share, with a total value of $37,000.00. Following the completion of the transaction, the chief executive officer now directly owns 1,480,119 shares of the company's stock, valued at $1,095,288.06. Learn More on Richard A. Miller 's trading history.

Are insiders buying or selling shares of Corvus Pharmaceuticals?

During the last year, Corvus Pharmaceuticals insiders bought shares 13 times. They purchased a total of 241,050 shares worth more than $249,595.30. The most recent insider tranaction occured on December, 20th when insider William Benton Jones bought 20,000 shares worth more than $15,800.00. Insiders at Corvus Pharmaceuticals own 29.7% of the company. Learn More about insider trades at Corvus Pharmaceuticals.

Information on this page was last updated on 12/20/2022.

Richard A. Miller Insider Trading History at Corvus Pharmaceuticals

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
12/13/2022Buy50,000$0.74$37,000.001,480,119View SEC Filing Icon  
9/28/2022Buy25,000$0.76$19,000.001,394,405View SEC Filing Icon  
9/20/2022Buy20,000$0.81$16,200.001,369,405View SEC Filing Icon  
6/27/2022Buy5,000$1.00$5,000.001,349,405View SEC Filing Icon  
6/24/2022Buy5,000$1.03$5,150.001,344,405View SEC Filing Icon  
6/6/2022Buy890$1.01$898.901,339,405View SEC Filing Icon  
6/2/2022Buy5,000$0.98$4,900.001,338,515View SEC Filing Icon  
3/31/2022Buy15,000$1.64$24,600.00View SEC Filing Icon  
3/17/2022Buy5,000$1.59$7,950.00View SEC Filing Icon  
3/15/2022Buy25,000$1.47$36,750.00View SEC Filing Icon  
8/20/2021Buy10,000$1.93$19,300.0035,714View SEC Filing Icon  
11/12/2019Buy272$2.90$788.80View SEC Filing Icon  
8/7/2019Buy7,500$3.56$26,700.00View SEC Filing Icon  
6/13/2019Buy343$3.52$1,207.36View SEC Filing Icon  
6/11/2019Buy15,212$3.49$53,089.88View SEC Filing Icon  
6/7/2019Buy9,212$3.37$31,044.44View SEC Filing Icon  
12/27/2018Buy20,000$3.29$65,800.00View SEC Filing Icon  
12/27/2018Buy20,000$3.29$65,800.00View SEC Filing Icon  
12/20/2018Buy10,000$4.40$44,000.00View SEC Filing Icon  
12/6/2018Buy5,000$5.99$29,950.00View SEC Filing Icon  
12/4/2018Buy1,502$5.95$8,936.90View SEC Filing Icon  
3/12/2018Buy100,000$8.50$850,000.00View SEC Filing Icon  
11/20/2017Buy10,000$10.79$107,900.00View SEC Filing Icon  
6/13/2017Buy25,000$9.88$247,000.00View SEC Filing Icon  
5/13/2016Buy30,300$10.00$303,000.00View SEC Filing Icon  
See Full Table

Richard A. Miller Buying and Selling Activity at Corvus Pharmaceuticals

This chart shows Richard A Md Miller's buying and selling at Corvus Pharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Corvus Pharmaceuticals Company Overview

Corvus Pharmaceuticals logo
Corvus Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in the development of immune modulator product candidates with the potential to treat solid cancers, T-cell lymphomas, autoimmune diseases, and infectious diseases. Its product pipeline includes B Cell Activator and Anti-CD73, Adenosine Production Inhibitor Anti-CD73, ITK Inhibitor, A2AR Inhibitor, Anti-CXCR2, and A2BR Inhibitor. The company was founded by Richard A. Miller, Peter A. Thompson, and Joseph J. Buggy on January 27, 2014 and is headquartered in Burlingame, CA.
Read More

Today's Range

Now: $0.81
Low: $0.81
High: $0.87

50 Day Range

MA: $0.87
Low: $0.77
High: $1.04

2 Week Range

Now: $0.81
Low: $0.70
High: $2.17


119,046 shs

Average Volume

110,814 shs

Market Capitalization

$37.83 million

P/E Ratio


Dividend Yield



A gold storm is coming…
“We are in the early stages of a mania – the calm before the storm.”...
[Full Story]